The Process Scientist will be responsible for supporting downstream process development activities.  The candidate for this position will be an integral member of the Process Development team and interact closely with other scientists within Protein Engineering and Manufacturing. He/she will provide production and development support for all pre-clinical programs.

 The successful candidate will be responsible for achieving the following objectives:

• Development and execution of protein purification activities supporting proof of concept studies in animal models
• Design of purification methods supporting pre-toxicology process development
• Generation of high quality technical reports required for technology transfer or regulatory requirements

Requirements:

PhD, MS with 3+ years’ or BS with 5+ years’ industry experience in analytical, biophysical, biochemistry, molecular/cell biology, chemical engineering or related field

 Experience with and knowledge of separation sciences, process engineering, purification development, chromatography, bio-separation

 Knowledge of glycoproteins, enzymes, biophysical/ biochemical characterization and bio-analytical sciences is desirable

Industry experience with these activities as part of a technical role in the support of pre-clinical stage strongly preferred

Detail-oriented personality and ability to work productively in an interdisciplinary team and fast-paced environment

Ability to work successfully with contract manufacturing and research organizations

Commitment to operational excellence  

Synageva  BioPharma  is  a  publicly  traded  biopharmaceutical  company  with headquarters, research and development facilities in Lexington, MA, and research and production facilities in Athens, GA. Synageva is dedicated to developing novel orphan treatments for rare diseases. Our lead program, sebelipase alfa (formerly SBC-102), an enzyme replacement therapy for LAL Deficiency, is in global clinical trials and has been granted orphan designation by the FDA, the European Medicines Agency, and the Japanese Ministry of Health, Labour and Welfare. LAL Deficiency is a rare, serious and devastating disease that leads to significant morbidity and mortality.  Synageva has additional orphan products in various stages of preclinical development. To ensure that these therapeutic candidates reach patients in need, Synageva has recruited a team with a proven track record of manufacturing, discovery, development, and commercial success within rare diseases.

Our mission  is to  deliver  breakthrough medicines  globally  for  patients suffering from   rare,  devastating diseases.   Achieving   this   will   result   in  a  sustainable business  that  can continue to positively impact   the  lives  of  patients and  their families, healthcare providers and our employees. Our success depends  upon our ability  to  seek and  retain principle-minded individuals who  share our  integrity, drive, energy and passion.